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Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder associated with amyloid-beta (Ab) plaque formation and
oxidative stress in the brain. Ghrelin has been proven to exert antioxidant activity and neuroprotection in different
neurological diseases. This study is going on to examine the effect of ghrelin on antioxidant status in the rat's model of
AD induced by Ab. Cognitive impairment was induced by intra-hippocampal administration of Ab (10 mg) in Wistar rats
and ghrelin (80 mg/kg) was administrated intraperitoneal for ten consecutive days. Behavior was assessed with Morris
water maze and passive avoidance tests. Malondialdehyde (MDA) level as a marker of lipid peroxidation was assessed
using the thiobarbituric acid. Catalase activity was assayed by the decomposition of H2O2. Antioxidant capacity was
determined using the FRAP method. Treatment with ghrelin decreased the hippocampus and serum MDA levels in
wild-type rodents and prevented an increase in hippocampal and serum MDA levels in animals receiving Ab. There was
no signiﬁcant change in the serum catalase activity between the studied groups. Hippocampus catalase activity was
reduced in the Ab group and treatment with ghrelin increased it. The antioxidant capacity of the hippocampus and
serum increased in the ghrelin-receiving control group. The hippocampus antioxidant capacity level decreased in the Ab
group, and treatment with ghrelin increased it, but there were no signiﬁcant changes in the serum antioxidant capacity of
animals receiving Ab. These results provide evidence that the administration of ghrelin has antioxidant properties and
protects against hippocampal lipid peroxidation in a rat model of AD.
Keywords: Alzheimer's disease, Ghrelin, Lipid peroxidation, Antioxidant capacity, Catalase

1. Introduction

A

lzheimer's disease (AD) is the most common
form of dementia, in which amyloid-beta
(Ab) plaques are found in the brain. One of the
complications of AD is the deterioration of mental
functions in the individual. Various cognitive abilities, such as memory, language, argument, and decision-making, are impaired with dementia [1].
Gradual memory impairment, one of the early signs
of AD, has been attributed to the deposition of Ab
plaques in the brain, especially in the hippocampus.
Two proteases, beta, and gamma-secretase produce

Ab peptide by the amyloid precursor protein (APP)
breakdown [2]. Increased production or defect in the
clearance of Ab causes the aggregation of toxic
amounts of Ab, which results in the formation of
plaques containing Ab in the brain which, in turn,
causes nerve damage and dementia [3]. Amyloid
plaques accumulate mainly in the isocortex in AD
[4]. In the Ab plaques cascade hypothesis, the
accumulation of Ab, especially Ab 1e42 in the brain,
creates a cascade of events that lead to neuronal
dysfunction and destruction [5,6]. Some studies
have shown that oxidative stress may be one of the
mechanisms of Ab to induce neuronal damage [7,8].
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Overproduction of reactive species, including free
radicals, and a weakening of antioxidant defense
systems are observed during oxidative stress [9].
Increasing reactive oxygen species (ROS) can play a
vital role in the pathogenesis of AD [10]. These
compounds cause damage to biological molecules
[11]. Some compounds and enzymes are involved in
the removal of ROS [12] such as catalase (CAT),
superoxide dismutase (SOD), and glutathione
peroxidase (GPX) [13]. The activity of enzymes
involved in the antioxidant system has decreased in
AD, leading to oxidative stress [14].
ROS can be created by damaged mitochondria or
produced by the innate immune in response to inﬂammatory stimuli. Ab and hyperphosphorylated
tau protein can play an essential role in mitochondrial dysfunction before the onset of amyloid plaques. Ab can trigger mitochondrial dysfunction by
interrupting the activity of complex III and complex
IV, and inhibiting directly the activity of the pyruvate
dehydrogenase and a-ketoglutarate dehydrogenase
enzymes. Ab also disrupts mitochondrial calcium
homeostasis and mitochondrial permeability transition pore [15]. Some evidence has shown that mitochondrial dysfunction leads to increased ROS
production leading to the early stages of AD [9].
Astrocytes and microglia are other sources of ROS
and RNS in the brain that can produce free radicals
when activated [15]. Oxidative stress occurs in the
early stages of AD and is associated with the presence of Ab as the cause of AD pathogenesis [16]. Ab
can be the source of ROS and the initiator of free
radical damage to biomolecules in the brain,
including fat peroxidation. In normal conditions,
antioxidant defense systems eliminate overproduced
ROS [10]. Excess Ab is associated with increased
oxidation of proteins, fats, and nucleic acids in the
hippocampus of Alzheimer's patients [16]. Oxidative
changes in RNA and DNA in the nucleus and
mitochondria, high levels of oxidized proteins, free
carbonyls, glycosylated products, peroxidation of
fats, and formation of aldehydes and ketones are
markers of oxidative stress. Some oxidative stress
markers increase in people's brain tissue in the early
or clinical stages of AD [17]. Evidence of low antioxidant capacity in the brain, CSF, and blood of
Alzheimer's patients has also been reported [18,19].
Ghrelin is a peptide hormone consisting of 28
amino acids secreted from gastric enteroendocrine
cells during starvation. Ghrelin exists as acyl ghrelin
and non-acylated (inactive) ghrelin [20]. Acyl ghrelin makes up only 10% of the circulating ghrelin. In
addition to the stomach, this hormone is secreted
from some other tissues in the body. It has several
biological effects, including appetite regulation,
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glucose metabolism, and energy homeostasis in the
hypothalamus [21]. Also, ghrelin and its receptor
(GHSR-1) are abundant in brain areas involved in
memory and learning and can affect neuronal activity and neurotransmitter release [22,23]. The
protective effect of ghrelin on neurons and its association with AD has been identiﬁed [24]. This
hormone has been reported to affect oxidative
stress. Ghrelin prevents a decrease in antioxidant
enzyme activity in rat plasma [25]. This hormone
reduces the amount of fat peroxidation in the rat
plasma [25] and increases the antioxidant defense in
the liver of rats [12]. It also has an antioxidant effect
on the ovary and testis of rats [26,27].
Considering the antioxidant effect of ghrelin in
various studies and the protective role of this hormone on neurons and its relationship with AD,
ghrelin's effect on the inhibition of oxidative stress
in Ab-induced AD rats was investigated in the
present study. First, after a histopathological study,
we examined the effects of ghrelin on memory and
learning. In the next step, we assessed the effect of
ghrelin treatment on the malondialdehyde (MDA)
level as a marker of lipid peroxidation, catalase activity, and antioxidant capacity in the extracted
hippocampus and serum of Ab-induced AD rats.

2. Method
2.1. Animals
Thirty adult male Wistar rats (250 ± 20 g) were
purchased from Pasteur Institute (Tehran, Iran). They
were housed in cages of three in a temperaturecontrolled holding room (23 ± 1  C), with humidity
~60%, and on a 12/12 h light/dark cycle (lights on at
8:00 AM). Standard laboratory procedures were followed. Food ad libitum and water were available. All
experiments were performed following the guidelines for the care and use of laboratory animals at
Shahid Beheshti University of Medical Sciences.
2.2. Drugs and agents
All chemicals were purchased from Merck unless
otherwise speciﬁed. Ab peptide 1e42 (SigmaeAldrich, Munich, Germany) was dissolved in
sterile PBS at a 2 mg/ml concentration and was
incubated at room temperature for 36 h [28]. Acylated ghrelin of rat (GL Biochem Ltd, Shanghai,
China) prepared in sterile normal saline at 1 mg/ml
concentration and kept at 20  C until use. Ketamine 10% and xylazine 2% were supplied by Alfasan (Woerden, Holland), and persocaine-E was
purchased from Darou Pakhsh (Tehran, Iran).
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2.3. Experimental design

2.4. Stereotaxic surgery

In this pilot study, the rats were randomly sorted
into ﬁve different groups, six rats in each. Each
experiment was conducted according to the
following schedule:
-The control group: The animals were intact and
did not receive any treatment.
-The sham group: Received 5 ml PBS in the hippocampus and, after one day, received daily intraperitoneal (i.p.) injections of 20 ml of saline for ten
consecutive days.
-The Ghrelin group: Received 5 ml PBS in the
hippocampus and, after one day, received a daily i.p
injection of 80 mg/kg of ghrelin for ten consecutive
days.
-The Ab group: Received a 10 mg (2 mg/ml) injection of Ab 1e42 in the hippocampus and, after
one day, were i.p injected with a daily dose of 20 ml
of saline for ten consecutive days.
-The Ghrelin-treated (Ab þ Ghrelin) group:
Received a 10 mg (2 mg/ml) injection of Ab 1e42 in
the hippocampus and, after one day, were i.p.
injected with 80 mg/kg of ghrelin every day for ten
consecutive days.
After performing behavioral tests (twelve days
after surgery), blood samples were taken from the
retro-orbital plexus, and serum was prepared. At
the end of the experiment, rats were anesthetized
with a ketamine/xylazine mixture and were sacriﬁced. Immediately, the hippocampus was excised
and frozen in liquid nitrogen. The RIPA lysis buffer
containing a protease inhibitor cocktail was used for
homogenizing samples. The homogenates were
centrifuged at 12000g at 4  C [29]. The supernatant
and serum were used to determine the catalase activity, the antioxidant capacity, and the malondialdehyde (MDA) level (Fig. 1).

Before surgery, each rat was anesthetized with an
i.p. injection of ketamine (85 mg/kg) and xylazine
(15 mg/kg). Adequate persocaine-E was injected
subcutaneously to prevent bleeding and induce
local anesthesia.
2.5. Micro-injection procedure
Each rat was mounted on a stereotaxic apparatus
(Stoelting, USA), and aggregated Ab 1e42 or PBS
was injected bilaterally into the Cornu Ammonis 3
(CA3) area of the hippocampus using a 5 ml Hamilton syringe (Fig. 2). The injection site was identiﬁed on the skull as follows: AP: 3.3 mm from the
bregma; ML: ±2.6 mm from the midline; DV:
3.7 mm from the skull surface based on Paxinos and
Watson's Atlas [30].
2.6. Histological evaluation
Histological studies were performed on the brain
tissue of some rats after surgery and Ab injection.
Rats were sacriﬁced in CO2 chambers, and the

Fig. 2. Diagram of the major divisions of the hippocampus. CA, Cornu
Ammonis; DG, dentate gyrus [31].

Fig. 1. Animal study design.
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brains were removed and stabilized. Then, dehydration, clariﬁcation, and molding steps were performed, and 5 mm thick sections were prepared with
a microtome. Nissl staining was used to stain nissl
bodies in the cytoplasm of neurons. For cell count,
identical sections (three rats in each group) were
used, and the number of dark cells/mm2 was
determined.
2.7. Behavioral studies
2.7.1. Morris water maze test
The Morris water maze (MWM) test began six
days after surgery. The water maze apparatus consisted of a black metal tank and habituation was
done one day before the training began. The daily
interval between tests was 30 s and the rat was
allowed to stay on the platform for 20 s before
removal from the tank. The training phase lasted for
three days. On the probe day, the time spent in the
target quadrant was recorded [32].
2.7.2. Passive avoidance test (PAT)
The passive avoidance behavior was done ten
days after surgery and was performed on two
consecutive days. The apparatus that was used to
evaluate the passive avoidance memory performance had two equal-sized light and dark compartments. The dark compartment was connected
to a shock source. Before the training trials, animals
were habituated to the apparatus by placing them
in the lightroom. After 5 s, the door was elevated.
When the rat entered the dark compartment with
all four feet, the door was closed, and the rat
remained there for 20 s. After that, the animal was
put into a temporary cage. After 30 min, the rat was
again conﬁned in the white compartment for 5 s.
The door was opened to let the animal enter the
dark chamber, and after the entrance, the door was
shut, but this time animals received a foot shock
(1.2 mA, 50 Hz, and 1.5 s). After 20 s, the rat was
returned to the temporary cage. After 2 min, the
same testing process was reiterated. The rats were
again placed in the light chamber to see whether
they stayed there for 2 min or not. It was considered
successful learning when the animals did not enter
the dark compartment during that period; otherwise, they would receive the same electric shock
again until they refrain from entering the dark box.
The memory retrieval test was performed to assess
the long-term memory of the animal 24 h after
learning. At this stage, the delay time of the animal
for the ﬁrst entry into the dark chamber was
assessed and the step-through latency (STL) was
recorded for 10 min [32].
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2.8. Measurement of lipid peroxidation
Lipid peroxidation was evaluated by measuring
the amount of malondialdehyde (MDA) by the
modiﬁed methods of Ohkawa based on TBA reactivity [33]. The standard curve is prepared with
1,1,3,3-tetraethoxypropane
(SigmaeAldrich,
Munich, Germany) solution. Brieﬂy, serum or hippocampal lysate (0.1 ml), SDS, and butylated
hydroxytoluene were mixed and then TBA in acetate buffer (pH 3.0) was added. The tubes were
incubated at 95  C in a water bath for 60 min and
after centrifugation, the supernatant was taken.
After this, the solution's adsorption was read at 532
and 572 nm, and the adsorption difference (A532 A572) was used in the calculations.
2.9. Catalase activity assay
Catalase activity was assayed by the decomposition of H2O2 as catalase substrate. Brieﬂy, 20 ml of
the sample was incubated with 100 ml of hydrogen
peroxide (65 mmol/ml in 60 mmol/L sodium-potassium phosphate buffer pH 7) for 1 min at 37  C.
After adding 100 ml of 4% ammonium molybdate the
yellow complex was measured at 405 nm. One
catalase activity unit was determined as the amount
of enzyme required to decompose one mmol
hydrogen peroxide/min at 37  C [34].
2.10. Measurement of antioxidant capacity
Antioxidant capacity was measured by the ferric
reducing antioxidant power (FRAP) assay. In this
method, the reduction of ferric ion (Fe3þ) to the
ferrous ion (Fe2þ) that forms a blue complex with
TPTZ (2,4,6-tri[2-pyridyl]-s-triazine) measures in an
acidic medium at 593 nm. The standard curve was
drawn using a ferrous sulfate solution. The FRAP solution contains acetate buffer (pH 3.6), TPTZ, and
ferric chloride. Brieﬂy, 10 ml serum was added to 300 ml
FRAP solution at 37  C, and its absorption was read in
front of the blank after 5 min at 595 nm [35].
2.11. Measurement of protein concentration
The protein concentration was determined according to the Bradford method [36]. The standard
curve was prepared using bovine serum albumin.
2.12. Statistical analysis
Data analysis was done through GraphPad Prism
software, version 8.0. The results are expressed as
the mean ± SD. The t-test and one-way analysis of
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variance (ANOVA) followed by Tukey's test were
used for data analysis. The statistical signiﬁcance
was achieved when p < 0.05.

3. Results
3.1. Histological studies
Histological examination with nissl staining in the
control, sham, ghrelin, and ghrelin treatment
groups shows pyramidal neurons with clear cytoplasm in the CA1 region of the hippocampus. The
size of pyramidal neurons was smaller, the nuclei
were wrinkled, the cytoplasmic range of the cell was
not well deﬁned in some cases and overall cell
density in the Ab group was lower than other
groups in the nissl staining of the CA1 region of the
hippocampus (Fig. 3A).
There was a signiﬁcant difference (p < 0.05) in the
number of dark cells/mm2 in the CA1 region of the
hippocampus between the control, sham, and ghrelin
groups with the Ab group. Ghrelin treatment
(Ab þ ghrelin group) signiﬁcantly (p < 0.05) decreased
the number of dark cells/mm2 in the CA1 region of
the hippocampus compared to the Ab group (Fig. 3B).
3.2. The effects of ghrelin in behavioral studies
The Morris water maze (MWM) test is used to test
the animal's spatial memory. There was no signiﬁcant
difference in the target quadrant's time in the control
and sham groups during the probe test. The time
spent in the target quadrant was signiﬁcantly
increased (p < 0.05) in rats in the ghrelin group
compared to the control and sham groups. The time
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spent in the target quadrant was reduced signiﬁcantly
(p < 0.05) in rats receiving Ab, and ghrelin treatment
(Ab þ ghrelin group) signiﬁcantly (p < 0.05) increased
it compared to the Ab group (Fig. 4A).
As shown in Fig. 4B, there was no signiﬁcant difference in step-through latency (STL) in the control
and sham groups on the passive avoidance test.
Ghrelin caused a signiﬁcant (p < 0.05) increase in
STL in rats compared to control and sham groups.
STL was reduced signiﬁcantly (p < 0.05) in the Ab
group compared to the other groups. Treatment with
ghrelin (Ab þ ghrelin group) signiﬁcantly increased
STL (p < 0.05) with respect to the Ab group.
3.3. The effects of ghrelin on lipid peroxidation
The hippocampus and serum MDA levels in rats
in the ghrelin group were signiﬁcantly reduced
(p < 0.05) compared to the control, sham, and Ab
groups. The amount of MDA in the hippocampus
and serum of rats in the Ab group was signiﬁcantly
increased (p < 0.05) compared to the control, sham,
and ghrelin groups. Administration of ghrelin
(Ab þ ghrelin group) signiﬁcantly (p < 0.05)
decreased the hippocampus and serum MDA level
compared to the Ab group (Fig. 5 and Table 1).
3.4. The effects of ghrelin on catalase activity
There was no signiﬁcant change in serum catalase
activity between the studied groups (Table 1). The
hippocampus catalase activity was reduced signiﬁcantly (p < 0.05) in rats in the Ab group compared to
the control, sham, and ghrelin groups. Treatment

Fig. 3. Histological studies. (A) Nissl staining of CA1 region of rat hippocampus in the control, sham, ghrelin, Ab, and Ab þ ghrelin groups, and (B)
Number of dark cells/mm2 in CA1 region of rat hippocampus in the control, sham, ghrelin, Ab, and Ab þ ghrelin groups (n ¼ 3). The data are shown
as means ± SD. *p < 0.05.
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Fig. 4. Behavioral studies. (A) Time spent in the target quadrant, (B) Step-through latency (STL) in the control, sham, ghrelin, Ab, and Ab þ ghrelin
groups (n ¼ 6). The data are shown as means ± SD. *p < 0.05.

serum of rats compared to the control and sham
groups, while Ab did not result in any change in this
parameter in the serum. The hippocampus antioxidant capacity level signiﬁcantly decreased (p < 0.05)
in the Ab group compared to the control, sham, and
ghrelin groups, and treatment with ghrelin
(Ab þ ghrelin group) signiﬁcantly increased
(p < 0.05) this parameter (Fig. 7 and Table 1).

4. Discussion

Fig. 5. The MDA level (nmol/mg protein) in the hippocampus of rats in
the control, sham, ghrelin, Ab, and Ab þ ghrelin groups (n ¼ 6). The
data are shown as means ± SD. *p < 0.05.

with ghrelin (Ab þ ghrelin group) signiﬁcantly
increased hippocampus catalase activity (p < 0.05)
compared to the Ab group (Fig. 6).
3.5. The effects of ghrelin on antioxidant capacity
Ghrelin caused a signiﬁcant (p < 0.05) increase in
antioxidant capacity level in the hippocampus and

AD is a progressive and chronic disease of the
nervous system, and its clinical features include
memory loss and personality changes [37]. In this
experimental study, Ab 1e42 was used to create a
similar Alzheimer's condition in the rat model and
ghrelin reduces oxidative stress due to its antioxidant properties and inhibiting fat peroxidation in
the brain. The majority of pyramidal neurons in the
hippocampus are densely packed into a single layer
divided into CA1 through CA4 regions. CA1 neurons are more sensitive to oxidative stress [38]. In
the cytoplasm of neurons, nissl bodies are stained
(blue-purple) by the nissl staining. This staining can
typically be used to detect necrosis in brain tissue
[39]. In the present study, histological studies on rats
receiving Ab indicate changes in CA1 hippocampal
tissue, and treatment with ghrelin reduces the effect
of Ab. These results are consistent with previous
studies on the effect of Ab and ghrelin on areas of
the brain, including the hippocampus, and tissue
changes in this area [40,41].
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Table 1. The MDA level (nmol/mL), catalase activity (U/mL), and antioxidant capacity (mM) in the rats' serum in the control, sham, ghrelin, Ab, and
Ab þ ghrelin groups (n ¼ 6).
MDA level (nmol/mL)
Catalase activity (U/mL)
Antioxidant capacity (mM)

Control

Sham

Ghrelin

2.1 ± 0.2
36.8 ± 1.5
338.3 ± 7.2

2.2 ± 0.1
34.7 ± 3.0
330.0 ± 29.1

1.6 ± 0.2*
36.5 ± 4.4
432.3 ± 42.6*,a,b,d

Ab þ ghrelin

Ab
,a,b,d

2.8 ± 0.2*
31.7 ± 2.1
352.3 ± 16.9*,c

,a,b,c,e

1.6 ± 0.2*,a,b,d
35.7 ± 2.1
407.0 ± 23.6

The data are shown as means ± SD. *p < 0.05.
a
vs control.
b
vs sham.
c
vs ghrelin.
d
vs Ab.
e
vs Ab þ ghrelin.

Fig. 6. The catalase activity (U/mg protein) in the hippocampus of rats
in the control, sham, ghrelin, Ab, and Ab þ ghrelin groups (n ¼ 6). The
data are shown as means ± SD. *p < 0.05.

The behavioral assessments in this study showed
that ghrelin signiﬁcantly increased memory function,
which supports previous ﬁndings on the effect of
ghrelin on memory function [22,42,43]. Recent studies
showed that ghrelin affects memory and cognition.
However, the precise mechanisms underlying ghrelin's modulation of the memory process are still uncertain [44]. Ghrelin injection into the rat amygdala,
hippocampus, and dorsal raphe nucleus increases
memory retention [45]. Moreover, ghrelin improves
dendritic synapse formation, long-term potentiation
(LTP) generation, and spatial learning and memory
[43]. Both subcutaneous and intracerebroventricular
(i.c.v.) administrations of ghrelin increase learning
and memory [43,44]. The ghrelin receptor is present
in the hippocampus and the injection of ghrelin agonists enhanced memory retention [46]. In the present study, intrahippocampal injection of Ab

Fig. 7. The antioxidant capacity (mmol/mg protein) in the rats' hippocampus in the control, sham, ghrelin, Ab, and Ab þ ghrelin groups
(n ¼ 6). The data are shown as means ± SD. *p < 0.05.

signiﬁcantly reduced memory function, and ghrelin
treatment signiﬁcantly compensated for it, which is
consistent with previous ﬁndings regarding the effect
of ghrelin on memory in rats with AD [30,41]. We
observed that the post-training injection of ghrelin
improves the consolidation of hippocampus-dependent forms of memory in the absence of any pathology. Chronic administration of ghrelin may improve
memory impairment and alleviate cognitive
dysfunction in AD patients [47]. A recent study using
nuclear magnetic resonance (NMR) to identify metabolites shows that the intracerebroventricular
(i.c.v.) ghrelin injection improves memory and
cognitive functions in the animal model of AD [48].
Consistent with these reports, we observed that Abinjected rats showed spatial memory deterioration,
and ghrelin administrations signiﬁcantly attenuated
this impairment.
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Our data show that the hippocampus and serum
level of MDA in the ghrelin group was signiﬁcantly
reduced. Numerous studies have been performed to
assess the antioxidant effect of ghrelin. The effect of
Ghrelin has been reported to reduce the amount of
MDA in the brain and plasma of rats. In addition,
there is a decrease in antioxidant enzyme activity in
the rat plasma [25]. MDA is an end-product of lipid
peroxidation. Lipid peroxidation is a critical criterion
for oxidative stress and is in the opposite ratio to
antioxidant properties. In this study, the hippocampus and serum level of MDA in the Ab group
showed a signiﬁcant increase. The results support
the hypothesis that oxidative stress is involved in
AD. Previous studies have shown that Ab may play a
role in mitochondrial damage and increased ROS
production. Increased fat peroxidation has been
observed in the early stages of AD in patients' brains
[17]. Accordingly, antioxidants, including ghrelin,
may be used to treat or prevent AD [19]. Increased
lipid peroxidation markers in patients with mild
cognitive impairment indicate that increased lipid
peroxidation may be a primary event in AD progression [17]. High MDA levels are seen in different
brain areas, cerebrospinal ﬂuid (CSF), and serum in
patients with AD [18,49]. Moreover, the increase in
oxidative stress and peroxidation products results in
the overexpression of antioxidant enzymes, such as
SOD and heme oxygenase 1 [50,51]. Several hypotheses explain the production of ROS in AD. Some
authors believe that the Ab oligomer potentially
produces H2O2. Others believe that Ab is involved in
the production of ROS by binding to redox-active
metal ions or physiological reducing agents such as
ascorbate. However, none of these hypotheses
completely explain the molecular mechanisms
responsible for the source of oxidative stress [52,53].
In the present study, the hippocampal levels of MDA
in the group receiving Ab þ ghrelin was signiﬁcantly
decreased compared to the group receiving Ab. This
ﬁnding indicates that ghrelin, due to its antioxidant
properties, can play a role in reducing the rate of fat
peroxidation in AD. To our knowledge, this is the
ﬁrst report showing that ghrelin reduces MDA production in AD. Ghrelin inhibits the activation of
microglia inﬂammation and increases the protein
UCP2 in the mitochondria. This protein enhances
neuroprotection by reducing the production of ROS
and increasing mitochondrial biogenesis. Therefore,
the neuroprotective role of ghrelin in the brain may
be dependent on UCP2. These neuroprotective effects of ghrelin appear to be mediated by activation
of its receptor (GHSR-1) because they are eliminated
by drug blocking or genetic deletion of the receptor
[54]. Ghrelin was reported to possess anti-oxidative
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effects in MES23.5 cells that were subjected to the
mitochondrial complex 1 inhibitor with 1-methyl-4phenylpyridinium (MPP), reducing MDA formation
in these cells [55,56]. Also, ghrelin has been shown to
inhibit the apoptosis-promoting protein glycogen
synthase kinase-3, improve Ab clearance through an
unknown pathway and reduce the toxicity of Ab and
inﬂammatory cytokines in AD [54]. Stimulation of
GHSR1a by ghrelin enhances autophagy, prevents
the accumulation of Ab peptides, and facilitates
autophagy-mediated degradation of autophagosomes containing Ab [23]. Numerous studies have
been performed on the antioxidant effect of ghrelin.
The effect of ghrelin in reducing the amount of MDA
in the brain and plasma of rats, and preventing a
decrease in antioxidant enzyme activity in the rat
plasma has been reported [25]. Ghrelin also promotes antioxidant defense in the liver of the rat [12].
Ghrelin attenuates negative effects on sperm parameters and enhances the fertility of the mice
exposed to cyclophosphamide [57]. Antioxidant effects of ghrelin in rat ovaries and testis have been
reported [26,27]. Antioxidants have been extensively
studied to prevent some diseases. Some natural
compounds with antioxidant properties have been
studied as adjunctive therapy for some neurological
disorders, including AD [58,59]. Such antioxidants
have been reported to protect against extracellular
and intracellular ROS. Because oxidative stress has
been involved in the onset and progression of AD,
the possibility of using antioxidants to prevent and
treat AD is important. Antioxidant therapy can be
considered a promising and low-risk treatment
strategy for AD [14,50]. Thus. Ghrelin's anti-oxidative
properties might be beneﬁcial for the treatment of
AD.
In the present study, a signiﬁcant decrease in
hippocampus catalase activity was found in the Ab
group, and treatment with ghrelin compensates for
this reduction. A decrease in catalase activity has
been observed in a streptozotocin-rat model of AD
[29]. Previous studies have shown that catalase activity was signiﬁcantly decreased in the brain of
patients with AD [49,60]. Catalase is one of the most
critical enzymes in the antioxidant system that
converts hydrogen peroxide to water and oxygen
[36]. Ab causes the accumulation of hydrogen
peroxide in various ways. It has been observed that
direct binding of Ab to catalase leads to a decrease
in catalase activity [61].
In the present study, antioxidant capacity in the
hippocampus and serum of rats in the ghrelin
receiving group signiﬁcantly increased. In previous
studies, ghrelin prevents a decrease in antioxidant
capacity in rat plasma [25]. This change can be
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attributed to ghrelin's ability to increase antioxidants and reduce ROS. The serum antioxidant capacity in the Ab group did not signiﬁcantly change,
but the hippocampal antioxidant capacity reduced,
and ghrelin treatment increased this parameter. The
low molecular weight antioxidants include ascorbate, uric acid, a-tocopherol, and glutathione, which
are important in preventing tissue damage. The
FRAP method to evaluate antioxidant capacity is
based on reducing Fe3þ to Fe2þ under acidic conditions. In this situation, hydrophilic materials such
as ascorbate are evaluated that can transfer electrons to Fe3þ [62]. Ascorbate is a vital antioxidant
molecule in the brain that can be rapidly accumulated in the brain and assessed by the FRAP method
[63]. Decreased antioxidant activity in CSF and
plasma of AD patients can be attributed to a
decrease in the amount of ascorbate due to the reaction with ROS in this condition [63,64].
The hippocampus antioxidant capacity level
decreased in the Ab group, and treatment with
ghrelin increased it in this study. This change can be
due to ghrelin's effect on reducing ROS. One of the
proteins that play an essential role in regulating the
antioxidant system is the Nrf2 (nuclear factorerythroid 2-related factor 2) protein. Nrf2 can be
associated with cellular defense against ROS, and its
activity has been observed to decrease with age and
with degenerative disorders [65]. Recent studies
indicate the role of the Nrf2 signaling pathway in
protecting against neurotoxicity induced by Ab and
reducing cell death due to oxidative stress [66]. An
association between Ab, oxidative stress, and Nrf2
can be considered. Recent studies have shown
ghrelin's effect on increasing the expression of the
Nrf2 gene and protein in the brain following hemorrhage in mice [67]. Based on this, it can be hypothesized that ghrelin may play a role in
strengthening the antioxidant system in the brain in
AD by acting on the Nrf2 protein.
In Conclusion, according to the available evidence, lack of protection against ROS production in
the brain can be one of the causes of AD progression. Ghrelin can play a protective role in AD due to
its antioxidant properties and inhibiting fat peroxidation in the brain.
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